ѻý

<ѻý class="page-title">Meeting Coverage

FSR

<ѻý class="page-description">Florida Society of Rheumatology
CV Risk in RA: Questions Remain

TARGET study should fill in the clinical gaps

image
<ѻý class="section_title">Latest FSR Meeting Coverage
Rheumatic Adverse Events on the Rise with Cancer Therapies

With immune checkpoint inhibition, rheumatic adverse events may become more common than RA

July 15, 2018